What question did this study set out to answer?

This research aims to investigate the effects of lovastatin on vascular smooth muscle cell proliferation in the context of restenosis.

Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates lovastatin's effect on human vascular smooth muscle cell growth, suggesting potential interventions for restenosis.

This research aims to investigate the effects of lovastatin on vascular smooth muscle cell proliferation in the context of restenosis.
Cultured human vascular smooth muscle cells from saphenous vein and graft stenoses were assessed.
Cells were treated with lovastatin at concentrations of 2 microM and 10 microM for 14 days, measuring proliferation and thymidine uptake.
Reversal experiments were conducted using mevalonate and farnesol to analyze the pathways involved.
Lovastatin (2 microM) inhibited proliferation by 42% in saphenous vein-derived cells and 32% in graft stenoses, not significantly different.
At 10 microM, lovastatin reduced [methyl 3H]-thymidine uptake by 51% in saphenous vein-derived cells, significantly preventing cell division.
Mevalonate completely reversed lovastatin's effects, while farnesol counteracted the antiproliferative response without significant impact from cholesterol.

Munro et al. (1994) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates lovastatin's effect on human vascular smooth muscle cell growth, suggesting potential interventions for restenosis.

This research aims to investigate the effects of lovastatin on vascular smooth muscle cell proliferation in the context of restenosis.
Cultured human vascular smooth muscle cells from saphenous vein and graft stenoses were assessed.
Cells were treated with lovastatin at concentrations of 2 microM and 10 microM for 14 days, measuring proliferation and thymidine uptake.
Reversal experiments were conducted using mevalonate and farnesol to analyze the pathways involved.
Lovastatin (2 microM) inhibited proliferation by 42% in saphenous vein-derived cells and 32% in graft stenoses, not significantly different.
At 10 microM, lovastatin reduced [methyl 3H]-thymidine uptake by 51% in saphenous vein-derived cells, significantly preventing cell division.
Mevalonate completely reversed lovastatin's effects, while farnesol counteracted the antiproliferative response without significant impact from cholesterol.

Munro et al. (1994) studied this question.

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark